E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Neonatal hyperbilirubinemia
Hiperbilirubinemia neonatal |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10020580 |
E.1.2 | Term | Hyperbilirubinaemia neonatal |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the safety of 3 ascending doses of stannsoporfin in subjects with hyperbilirubinemia. |
|
E.2.2 | Secondary objectives of the trial |
To determine the efficacy and pharmacokinetics (PK) of 3 ascending doses of stannsoporfin in subjects with hyperbilirubinemia. An exploratory pharmacodynamic analysis will examine the relationship between stannsoporfin exposure and change in TSB from Baseline to 48 hours, post dosing of IMP. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Term and late preterm subjects (>=35 weeks and <43 weeks gestational age) - Risk factors for hemolytic disease to include subjects with ABO blood type incompatibility or Rh incompatibility (anti-C, c, D, E, or e) - A minimum birth weight of 2500 g (5.5 lbs) - Coombs test results available - Within 2 mg/dL below the threshold for PT per the AAP Guidelines (see Appendix A) at up to 12 hours of age or within 3 mg/dL below the threshold for PT at >12 to 48 hours of age, inclusive (see Appendix B) - Willingness for parents/guardians to adhere to recommendations regarding light precautions - Written informed consent obtained from parents/guardians |
|
E.4 | Principal exclusion criteria |
- Family history of glucose-6-phosphate dehydrogenase (G6PD) deficiency - Clinical suggestion of neonatal thyroid disease or current uncontrolled thyroid disease in the mother (maternal Hashimoto´s disease is not exclusionary) - Treatment or need for treatment in the neonate with medications that may prolong the QT interval (see Appendix C) (erythromycin ointment for eye prophylaxis is permitted), family history of Long QT syndrome or family history of Sudden Infant Death syndrome - Known porphyrias or risk factors for porphyrias, including family history - A maternal history of systemic lupus erythematosus - Maternal use of phenobarbital 30 days before, or after delivery, if breastfeeding - Maternal current drug or alcohol abuse, or maternal history of drug or alcohol abuse, that, in the opinion of the Investigator, would not make the subject a suitable candidate for participation in the clinical trial - Apgar score =< 6 at age 5 minutes - Significant congenital anomalies or infections - Cardiorespiratory distress, defined as a respiratory rate >60 breaths per minute, at time of enrollment, unless a diagnosis of transient tachypnea of the newborn has been made - Any abnormal auditory or ophthalmologic findings at Screening: Subjects who fail initial auditory screen may be rescreened - Any excess risk of requiring surgery or exposure to operating room lights in the foreseeable future - Clinically significant abnormalities on screening laboratory evaluation - Elevated direct or conjugated bilirubin (>1.0 mg/dL if the TSB is <5.0 mg/dL or >20% of the TSB if the TSB is >= 5.0 mg/dL) - Persistent hypoglycemia (blood glucose <40 mg/dL) despite standard-of-care treatment - Alanine aminotransferase >2 times the upper limit of normal (ULN) or aspartate aminotransferase >3 times the ULN - Abnormal renal function defined as creatinine and/or blood urea nitrogen >2 times the ULN - Any blood smear finding of structural red cell abnormalities, such as spherocytosis, not caused by isoimmune hemolysis - Temperature instability defined as temperature consistently (3 consecutive times) <36ºC and/or >37.5ºC axillary - Use of photosensitizing drugs or agents (see Appendix D) - Use of intravenous immunoglobulin (IVIG) or albumins - Postdelivery treatment with medications that are known or suspected to displace bilirubin from albumin (eg, ceftriaxone or sulfa-based antibiotics) - Other serious morbid conditions, eg, pulmonary disease, cardiovascular disease - Exposure to any investigational medications or devices after delivery, or participation in another clinical trial while participating in this trial - Any other concurrent medical condition that, in the opinion of the Investigator, makes the subject unsuitable for the clinical trial - Unwillingness for parents/guardians to adhere to recommendations regarding light precautions |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy outcome will be based on total serum bilirubin (TSB) measurements adjusted for phototherapy (PT) initiation at both baseline and at 48 hours after treatment. In particular, the change in adjusted TSB levels from baseline to 48 hours after treatment will be considered.
Secondary efficacy endpoints are the following: - Unadjusted change from baseline to 48 hours in TSB measurements - Adjusted and unadjusted change from baseline in TSB measurements at various other timepoints - Proportion of subjects who require phototherapy (PT)/exchange transfusion - Time to PT/exchange transfusion - Duration of PT - Time to hospital discharge
Safety will be based on the following variables: - Reported adverse events (AEs) - Vital sign measurements - Physical examinations - Electrocardiogram (ECG) recordings - Hearing assessments - Vision assessments - Neurological assessments - Dermatological reactions - Clinical laboratory tests |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 20 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Each subject receives only a single dose. End of trial will be the last patient's last visit. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 7 |
E.8.9.2 | In all countries concerned by the trial days | 0 |